↑ Grab this Headline Animator

Research and Markets Pharmaceutical Research Profiting from Cellbased...

February 3, 2005 -- Advances in molecular imaging are prompting a rapid change in how we visualize disease processes and therapeutic interventions at the molecular level, supplanting purely structural information with valuable functional data. Molecular Imaging Comes of Age: Applications and Impacts in Discovery, Clinical Trials, and Medical Practice provides insight into the technologies that will impact healthcare over the next five years from early research to the delivery of care. The report presents a comprehensive assessment of the latest trends and developments in molecular imaging, enhanced by the insights of opinion leaders from industry and academia. A market outlook completes the analysis.



Molecular imaging has become a business that covers the spectrum from basic cell biology to drug discovery and disease monitoring. The forms in which it has been commercialized are also highly diverse, indicating both substantial growth opportunities for companies competing in this space, as well as new and improved methodologies for researchers. Molecular Imaging Comes of Age evaluates the competing technologies and their applications in three key areas:



Discovery

The pharmaceutical industry has placed a large bet on molecular imaging. While monitoring and guiding of drug therapies with PET will help clinicians to use drugs in a more targeted fashion, molecular imaging's core role for the pharmaceutical industry is in drug discovery and development. The report examines ways in which pure research is already profiting from cell - based molecular imaging, which will continue to be based on fluorescence, bioluminescence, and confocal microscopy. Applications in small animal imaging, lead characterization, and lead optimization are also discussed. The insights into basic cell biology that this research is yielding today will form the basis of drug development during the second half of the decade, as the results are absorbed by the pharmaceutical industry.



Clinical Applications

The report highlights clinical applications of molecular imaging technology in cancer, particularly ovarian cancer, as well as cardiovascular disease and inflammation. Experimental clinical applications that reach far beyond these fields, including for instance neuropsychiatry, angiogenesis, and the monitoring of gene therapy are also covered.



Clinical Trials

All regulatory authorities demand that drug developers present a reasonable amount of scientific proof for claims that the candidate compound binds to the designated molecular target, or exerts the expected physiological effect in the target tissue(s). In many cases, molecular imaging will be the method of choice for obtaining such data. The report discusses the general regulatory issues that will impact the use of imaging agents in clinical trials.



Expert Commentaries

- Merck

- Pfizer

- CTI Molecular

- Genentech

- Stanford

- Johns Hopkins

- GammaMedica

- Novartis



Selected Company Profiles

- Siemens Medical Solutions

- GE Healthcare

- Philips Medical Systems - Molecular Imaging Unit

- CTI Molecular Imaging

- Applied Imaging Corp.

- Norak Biosciences, Inc.

- GammaMedica, Inc.

- Kereos, Inc.

- OptoSonics, Inc.

- Xenogen Corp.

- Molecular Imaging Research, Inc.

- Visen Medical, Inc.



For more information visit http://www.researchandmarkets.com/reports/c12464



Laura Wood

Senior Manager

Research and Markets

e-mail protected from spam bots

Fax: +353 1 4100 980

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Security | Special Ops | tactical strategic solutions |

---

4939 readers online...

, Local News